SCHEMBL2073114

SCHEMBL2073114

N#Cc1ccccc1C1=CC2CCC(C1)N2C(=O)N1CCCc2ccccc21

nearest known ligand 0.45

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 7/20 0.45
SMN1; SMN2 Q16637 1/20 0.42
POLB P06746 1/20 0.42
UCHL1 P09936 1/20 0.41
USP30 Q70CQ3 1/20 0.41
NOTUM Q6P988 1/20 0.40
TSHR P16473 2/20 0.40
SLC22A12 Q96S37 2/20 0.39
ALDH1A1 P00352 1/20 0.38
MAPK1 P28482 1/20 0.38
MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2073118 1.00 HSD11B1 (0.45) HSD11B1SMN1; SMN2POLBUCHL1USP30
SCHEMBL4087976 0.93 HSD11B1 (0.40) HSD11B1SMN1; SMN2POLBUCHL1USP30
SCHEMBL4087984 0.93 HSD11B1 (0.40) HSD11B1SMN1; SMN2POLBUCHL1USP30
SCHEMBL2071794 0.86 HSD11B1 (0.45) HSD11B1SMN1; SMN2POLBUCHL1USP30
SCHEMBL2071793 0.86 HSD11B1 (0.45) HSD11B1SMN1; SMN2POLBUCHL1USP30
SCHEMBL2072978 0.86 PDE4B (0.48) HSD11B1SMN1; SMN2POLBNOTUMTSHR
SCHEMBL2071056 0.86 PDE4B (0.48) HSD11B1SMN1; SMN2POLBNOTUMTSHR
SCHEMBL2072975 0.86 PDE4B (0.48) HSD11B1SMN1; SMN2POLBNOTUMTSHR
SCHEMBL2071055 0.86 PDE4B (0.48) HSD11B1SMN1; SMN2POLBNOTUMTSHR
SCHEMBL2070282 0.85 HSD11B1 (0.45) HSD11B1SMN1; SMN2POLBNOTUMTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7897773-B2 Urea derivatives of tropane, their preparation and their therapeutic application SANOFI-AVENTIS (FR) 2011-03-01 US disclosed
US-20100324084-A1 UREA DERIVATIVES OF TROPANE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2010-12-23 US disclosed
EP-2046791-B1 UREA DERIVATIVES OF TROPANE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI AVENTIS (FR) 2010-03-24 EP disclosed
US-20090170894-A1 UREA DERIVATIVES OF TROPANE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170894-A1 UREA DERIVATIVES OF TROPANE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION HSD11B1, ADRA1D, HSD17B1 HSD11B1 1/4885SMN1; SMN2 2670/4885POLB 463/4885
US-20100324084-A1 UREA DERIVATIVES OF TROPANE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION HSD11B1, ADRA1D, HSD17B1 HSD11B1 1/4885SMN1; SMN2 2670/4885POLB 463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.